Amendments to the Claims

1-2. (Cancelled)

3. (Currently amended) ~~The~~ An oral sustained-release tablet ~~according to claim 1~~ comprising a pharmaceutical composition containing 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide as an active ingredient in an amount of 0.2 to 0.7 mg, wherein the pharmaceutical composition contains 18 to 73wt% of hydroxypropylmethylcellulose as a gel-forming material.

4. (Currently amended) The oral sustained-release tablet according to claim ~~1~~ 3, obtained by mixing a granular composition ~~containing~~ , in which 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide is uniformly dispersed by means of fluidized bed granulation method, with a composition containing a gel-forming material which is hydroxypropylmethylcellulose to manufacture a granular formulation for making tablets.

5. (Currently amended) The oral sustained-release tablet according to claim 4, wherein the granular composition is manufactured by using a solution of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide ~~containing granules are manufactured by using a solution of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide~~ and by spraying the solution on partly pregelatinized starch.